| [1] |
Jayakrishnan T, Ng K. Early-onset gastrointestinal cancers: a review[J]. JAMA. 2025, 334(15): 1373-1385. DOI: 10.1001/jama.2025.10218.
|
| [2] |
Yu L, Luo X Y, Zhang Z J, et al. Reinforced immunotherapy of M1 macrophage-derived exosomes with CEL on TNBC via regulating macrophage functions[J]. J Adv Res, 2026, 82: 1163-1178. DOI: 10.1016/j.jare.2025.07.024.
|
| [3] |
Foersch S, Glasner C, Woerl A C, et al. Multistain deep learning for prediction of prognosis and therapy response in colorectal cancer[J]. Nat Med, 2023, 29(2): 430-439. DOI: 10.1038/s41591-022-02134-1.
|
| [4] |
Tong G J, Shen Y, Li H, et al. NLRC4, inflammation and colorectal cancer (review)[J]. Int J Oncol, 2024, 65(4): 99. DOI: 10.3892/ijo.2024.5687.
|
| [5] |
Zhang W T, Xiang Y H, Ren H, et al. The tumor microbiome in cancer progression: mechanisms and therapeutic potential[J]. Mol Cancer, 2025, 24(1): 195. DOI: 10.1186/s12943-025-02403-w.
|
| [6] |
Kotani D, Oki E, Nakamura Y, et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer[J]. Nat Med, 2023, 29(1): 127-134. DOI: 10.1038/s41591-022-02115-4.
|
| [7] |
Wang A H, Wang Y, Du C X, et al. Pyroptosis and the tumor immune microenvironment: a new battlefield in ovarian cancer treatment[J]. Biochim Biophys Acta BBA Rev Cancer, 2024, 1879(2): 189058. DOI: 10.1016/j.bbcan.2023.189058.
|
| [8] |
Audisio A, Gallio C, Velenik V, et al. Total neoadjuvant therapy for locally advanced rectal cancer[J]. JAMA Oncol, 2025: e252026. DOI: 10.1001/jamaoncol.2025.2026.
|
| [9] |
Gómez-Neva M E, Pulido-Ramirez E, Ibañez-Rodriguez L J, et al. Non-pharmacological interventions for side effects of antineoplastic chemotherapy prioritized by patients: systematic review[J]. Rev Cuid, 2024, 15(3): e3612. DOI: 10.15649/cuidarte.3612.
|
| [10] |
Liang D, Ning M, Xie H, et al. Radiotherapy side effects: comprehensive proteomic study unraveled neural stem cell degenerative differentiation upon ionizing radiation[J]. Biomolecules, 2022, 12(12): 1759. DOI: 10.3390/biom12121759.
|
| [11] |
Bando H, Ohtsu A, Yoshino T. Therapeutic landscape and future direction of metastatic colorectal cancer[J]. Nat Rev Gastroenterol Hepatol, 2023, 20(5): 306-322. DOI: 10.1038/s41575-022-00736-1.
|
| [12] |
Wu Z H, Xiao C, Long J, et al. Mitochondrial dynamics and colorectal cancer biology: mechanisms and potential targets[J]. Cell Commun Signal, 2024, 22(1): 91. DOI: 10.1186/s12964-024-01490-4.
|
| [13] |
Sun L, Cao X L, Zhou B C, et al. Tumor-associated mesenchymal stem/stromal cells in tumor microenvironment and carcinogenesis[J]. Exp Hematol Oncol, 2025, 14(1): 97. DOI: 10.1186/s40164-025-00688-7.
|
| [14] |
Siegel R L, Wagle N S, Cercek A, et al. Colorectal cancer statistics, 2023[J]. CA A Cancer J Clinicians, 2023, 73(3): 233-254. DOI: 10.3322/caac.21772.
|
| [15] |
Sun C, Liu Y, Huang Y, Li B, Rang W. Colorectal cancer incidence and mortality trends and analysis of risk factors in China from 2005 to 2015. Int J Gen Med. 2021, 14: 9965-9976. DOI: 10.2147/IJGM.S344448. PMID: 34984021; PMCID: PMC8709550.
|
| [16] |
Mcclelland P H, LiuT, Ozuner G. Early-onset colorectal cancer in patients under 50 years of age: demographics, disease characteristics, and survival[J]. Clinical Colorectal Cancer, 2022, 21(2): e135-e144. DOI: 10.1016/j.clcc.2021.11.003.
|
| [17] |
Siegel R L, Wagle N S, Star J, et al. Colorectal cancer statistics, 2026[J]. CA Cancer J Clin. 2026, 76(2): e70067. DOI: 10.3322/caac.70067.
|
| [18] |
Haghighatdoost F, Mehrabani-Zeinabad K, Hajihashemi P, et al. Burden of colorectal cancer and its risk factors in the North Africa and Middle East (NAME) region, 1990-2019: a systematic analysis of the global burden of disease study[J]. BMC Public Health, 2024, 24(1): 557. DOI: 10.1186/s12889-024-18027-6.
|
| [19] |
|
| [20] |
Ciardiello F, Ciardiello D, Martini G, et al. Clinical management of metastatic colorectal cancer in the era of precision medicine[J]. CA Cancer J Clin, 2022, 72(4): 372-401. DOI: 10.3322/caac.21728.
|
| [21] |
Afify S M, Hassan G, Seno A, et al. Cancer-inducing niche: the force of chronic inflammation[J]. Br J Cancer, 2022, 127(2): 193-201. DOI: 10.1038/s41416-022-01775-w.
|
| [22] |
Stevens L E, Peluffo G, Qiu X T, et al. JAK-STAT signaling in inflammatory breast cancer enables chemotherapy-resistant cell states[J]. Cancer Res, 2023, 83(2): 264-284. DOI: 10.1158/0008-5472.CAN-22-0423.
|
| [23] |
Bhat A A, Nisar S, Singh M, et al. Cytokine- and chemokine-induced inflammatory colorectal tumor microenvironment: emerging avenue for targeted therapy[J]. Cancer Commun (Lond), 2022, 42(8): 689-715. DOI: 10.1002/cac2.12295.
|
| [24] |
Butkute A, Baltramonaitis M, Malmige S, et al. Targeting stemness pathways modulates macrophage polarization and reprograms the tumor microenvironment[J]. Front Immunol, 2025, 16: 1513404. DOI: 10.3389/fimmu.2025.1513404.
|
| [25] |
Hisamatsu T, Miyoshi J, Oguri N, et al. Inflammation-associated carcinogenesis in inflammatory bowel disease: clinical features and molecular mechanisms[J]. Cells, 2025, 14(8): 567. DOI: 10.3390/cells14080567.
|
| [26] |
Elias E E, Lyons B, Muruve D A. Gasdermins and pyroptosis in the kidney[J]. Nat Rev Nephrol, 2023, 19(5): 337-350. DOI: 10.1038/s41581-022-00662-0.
|
| [27] |
Zhang W T, Liu Z W, Zhu J W, et al. Bioorthogonal disruption of pyroptosis checkpoint for high-efficiency pyroptosis cancer therapy[J]. J Am Chem Soc, 2023, 145(30): 16658-16668. DOI: 10.1021/jacs.3c04180.
|
| [28] |
Negro S, Pulvirenti A, Trento C, et al. Circulating tumor DNA as a real-time biomarker for minimal residual disease and recurrence prediction in stageⅡ colorectal cancer: a systematic review and meta-analysis[J]. Int J Mol Sci, 2025, 26(6): 2486. DOI: 10.3390/ijms26062486.
|
| [29] |
Wei X, Xie F, Zhou X X, et al. Role of pyroptosis in inflammation and cancer[J]. Cell Mol Immunol, 2022, 19(9): 971-992.
|
| [30] |
Qu Z L, Zhou J, Zhou Y D, et al. Mycobacterial EST12 activates a RACK1-NLRP3-gasdermin D pyroptosis-IL-1β immune pathway[J]. Sci Adv, 2020, 6(43): eaba4733.
|
| [31] |
Hargreaves D C, Horng T, Medzhitov R. Control of inducible gene expression by signal-dependent transcriptional elongation[J]. Cell, 2009, 138(1): 129-145. DOI: 10.1016/j.cell.2009.05.047.
|
| [32] |
Dong X C, Hu X M, Bao Y, et al. Brd4 regulates NLRC4 inflammasome activation by facilitating IRF8-mediated transcription of Naips[J]. J Cell Biol, 2021, 220(3): e202005148.
|
| [33] |
Yang F, Bettadapura S N, Smeltzer M S, et al. Pyroptosis and pyroptosis-inducing cancer drugs[J]. Acta Pharmacol Sin, 2022, 43(10): 2462-2473. DOI: 10.1038/s41401-022-00887-6.
|
| [34] |
Wang Y Q, Kanneganti T D. From pyroptosis, apoptosis and necroptosis to PANoptosis: a mechanistic compendium of programmed cell death pathways[J]. Comput Struct Biotechnol J, 2021, 19: 4641-4657. DOI: 10.1016/j.csbj.2021.07.038.
|
| [35] |
Rathinam V A K, Fitzgerald K A. Inflammasome complexes: emerging mechanisms and effector functions[J]. Cell, 2016, 165(4): 792-800. DOI: 10.1016/j.cell.2016.03.046.
|
| [36] |
Peng X, Na R S, Zhou W T, et al. Nuclear translocation of Gasdermin D sensitizes colorectal cancer to chemotherapy in a pyroptosis-independent manner[J]. Oncogene, 2022, 41(47): 5092-5106. DOI: 10.1038/s41388-022-02503-7.
|
| [37] |
Chen T, Wang Z, Zhong J, et al. Secoisolariciresinol diglucoside induces pyroptosis by activating caspase-1 to cleave GSDMD in colorectal cancer cells[J]. Drug Dev Res, 2022, 83(5): 1152-1166. DOI: 10.1002/ddr.21939.
|
| [38] |
Vafaei S, Taheri H, Hajimomeni Y, et al. The role of NLRP3 inflammasome in colorectal cancer: potential therapeutic target[J]. Clin Transl Oncol, 2022, 24(10): 1881-1889. DOI: 10.1007/s12094-022-02861-4.
|
| [39] |
Mowat C, Schiller D, Baker K. NLRP3 activation promotes cGAS/STING signaling and antitumor immunity by colorectal cancer cells[J]. Cancer Immunol Immunother, 2025, 74(8): 238. DOI: 10.1007/s00262-025-04088-y.
|
| [40] |
Zhang H L, Chang J, Sun C P, et al. Andrographolide and its sulfated metabolite alleviated DSS-induced inflammatory bowel disease through regulating inflammation and immune via MAPK/NLRP3 pathways and the balance of Th17/Treg cells[J]. Mol Immunol, 2025, 183: 313-320. DOI: 10.1016/j.molimm.2025.05.015.
|
| [41] |
Zhao Y, Sun Y, Ding Y X, et al. GL-V9, a new synthetic flavonoid derivative, ameliorates DSS-induced colitis against oxidative stress by up-regulating Trx-1 expression via activation of AMPK/FOXO3a pathway[J]. Oncotarget, 2015, 6(28): 26291-26307. DOI: 10.18632/oncotarget.4657.
|
| [42] |
Zhao L Y, Zhang X, Zhou Y F, et al. Parvimonas Micra promotes colorectal tumorigenesis and is associated with prognosis of colorectal cancer patients[J]. Oncogene, 2022, 41(36): 4200-4210. DOI: 10.1038/s41388-022-02395-7.
|
| [43] |
Fernandez-Rozadilla C, Timofeeva M, Chen Z S, et al. Deciphering colorectal cancer genetics through multi-omic analysis of 100, 204 cases and 154, 587 controls of European and East Asian ancestries[J]. Nat Genet, 2023, 55(1): 89-99.
|
| [44] |
Malla S B, Byrne R M, Lafarge M W, et al. Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer[J]. Nat Genet, 2024, 56(3): 458-472. DOI: 10.1038/s41588-024-01654-5.
|
| [45] |
Dasari A, Lonardi S, Garcia-Carbonero R, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study[J]. Lancet, 2023, 402(10395): 41-53.
|
| [46] |
Bektaş M, Burchell G L, Bonjer H J, et al. Machine learning applications in upper gastrointestinal cancer surgery: a systematic review[J]. Surg Endosc, 2023, 37(1): 75-89.
|
| [47] |
Zhou Z K, Ma Y H, Zhang D K, et al. Microbiome and fragmentation pattern of blood cell-free DNA and fecal metagenome enhance colorectal cancer micro-dysbiosis and diagnosis analysis: a proof-of-concept study[J]. mSystems, 2025, 10(5): e0027625. DOI: 10.1128/msystems.00276-25.
|
| [48] |
Yaeger R, Mezzadra R, Sinopoli J, et al. Molecular characterization of acquired resistance to KRASG12C-EGFR inhibition in colorectal cancer[J]. Cancer Discov, 2023, 13(1): 41-55. DOI: 10.1158/2159-8290.CD-22-0405.
|
| [49] |
Wang J Y, Li D M, Ye F Z, et al. Global epidemiology of early-onset digestive system malignancy: a systematic analysis for the global burden of disease study 2021[J]. J Gastroenterol Hepatol, 2025, 40(6): 1525-1535. DOI: 10.1111/jgh.17012.
|